This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Medina, A. Articles by Lipsitz, L. A. Search for Related Content PubMed PubMed Citation Articles by Medina, A. Articles by Lipsitz, L. A.

(Hypertension. 1997;29:828-834.)
© 1997 American Heart Association, Inc.

Articles

Effects of Central Muscarinic-1 Receptor Stimulation on Blood Pressure Regulation

Aharon Medina; Neil Bodick; Ary L. Goldberger; Margaret Mac Mahon; Lewis A. Lipsitz

the Hebrew Rehabilitation Center for Aged Research and Training Institute, the Beth Israel/Deaconess Medical Center Department of Medicine, Harvard Medical School, Boston, Mass, and Eli Lilly Laboratory for Clinical Research, Indianapolis, Ind.

Stimulation of central nervous system muscarinic-1 (M₁) receptors in animals increases blood pressure, heart rate, and sympathetic outflow. In Alzheimer's disease, stimulation of central M₁ receptors is reduced. When the oral formulation of the selective M₁ agonist xanomeline was tested for the treatment of Alzheimer's disease, an increased incidence of syncope was observed. Therefore, we used Alzheimer's disease as a model of relative M₁ deficiency to determine the effect of M₁ receptor stimulation on blood pressure regulation in humans. Eight Alzheimer's patients and 6 healthy age- and sex-matched subjects underwent blood pressure, heart rate, forearm vascular resistance, plasma norepinephrine, and heart rate variability measurements during 90 minutes after ingestion of xanomeline or placebo, then during 45 minutes of head-up tilt. Alzheimer's patients were studied on three occasions: after placebo, the first dose of xanomeline, and 3 days of xanomeline. Normal subjects were studied after placebo and the first dose of xanomeline. A subset of 5 Alzheimer's patients was studied with the peripheral muscarinic antagonist methscopolamine. Oral xanomeline increased supine systolic and diastolic blood pressures in normal subjects and heart rate and plasma norepinephrine in all subjects. During the placebo tilt, 0 of 8 Alzheimer's patients and 2 of 6 healthy subjects developed near-syncope, and during the first-dose xanomeline tilt, 4 of 8 Alzheimer's patients and 3 of 6 healthy subjects had near-syncope. The maximal decrease in systolic blood pressure during tilt was greater with xanomeline than placebo in both groups (P<.03). Methscopolamine did not prevent xanomeline-induced hypotension. Central M₁ receptor stimulation with the oral formulation of xanomeline in humans is associated with sympathetic stimulation under supine conditions and impaired baroreflex compensation during tilt. Alzheimer's patients, who presumably lack M₁ receptor activity, may have a reduced risk of tilt-induced syncope compared with normal subjects. Both groups, however, have enhanced susceptibility to hypotension and syncope when M₁ receptor activity is pharmacologically increased.

Key Words: orthostatic hypotension • syncope • tilt • xanomeline • aging • neurotransmitters • Alzheimer's disease

This article has been cited by other articles:

				W. Y. Chan, D. L. McKinzie, S. Bose, S. N. Mitchell, J. M. Witkin, R. C. Thompson, A. Christopoulos, S. Lazareno, N. J. M. Birdsall, F. P. Bymaster, et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia PNAS, August 5, 2008; 105(31): 10978 - 10983. [Abstract] [Full Text] [PDF]

				M. K. O. Grant and E. E. El-Fakahany Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 313 - 319. [Abstract] [Full Text] [PDF]